{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:26:06Z","timestamp":1789194366234,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Possibilities to improve the therapeutic efficacy of Lu-177\u2013PSMA-617 radionuclide therapy by modulation of target expression are being investigated. Knowledge on regulatory factors that promote prostate cancer (PCa) progression may contribute to targeting prostate cancer more effectively. We aimed at the stimulation of PCa cell lines using the substances 5-aza-2\u2032-deoxycitidine (5-aza-dC) and valproic acid (VPA) to achieve increased prostate-specific membrane antigen (PSMA) expression. PC3, PC3-PSMA, and LNCaP cells were incubated with varying concentrations of 5-aza-dC and VPA to investigate the cell-bound activity of Lu-177\u2013PSMA-617. Stimulation effects on both the genetically modified cell line PC3-PSMA and the endogenously PSMA-expressing LNCaP cells were demonstrated by increased cellular uptake of the radioligand. For PC3-PSMA cells, the fraction of cell-bound radioactivity was enhanced by about 20-fold compared to that of the unstimulated cells. Our study reveals an increased radioligand uptake mediated by stimulation for both PC3-PSMA and LNCaP cell lines. In perspective of an enhanced PSMA expression, the present study might contribute to advanced radionuclide therapy approaches that improve the therapeutic efficacy, as well as combined treatment options.<\/jats:p>","DOI":"10.3390\/ph16040538","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T04:09:50Z","timestamp":1680581390000},"page":"538","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Roswitha","family":"Runge","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Naumann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany"},{"name":"National Center for Tumor Diseases (NCT), D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Kotzerke","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brogsitter","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"911146","DOI":"10.3389\/fonc.2022.911146","article-title":"Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET\/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography\/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"Picchio","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_5","first-page":"855","article-title":"Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy","volume":"56","author":"Herrmann","year":"2015","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_6","first-page":"1170","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Berglund, A., Matta, J., Encarnacion-Medina, J., Ortiz-Sanchez, C., Dutil, J., Linares, R., Marcial, J., Abreu-Takemura, C., Moreno, N., and Putney, R. (2021). Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules, 12.","DOI":"10.3390\/biom12010002"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/geno.2000.6446","article-title":"A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1","volume":"73","author":"Watt","year":"2001","journal-title":"Genomics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/CBI20100568","article-title":"Epigenetic inactivation of PCDH10 in human prostate cancer cell lines","volume":"35","author":"Li","year":"2011","journal-title":"Cell Biol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic Therapies for Cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMcibr1514673","article-title":"Epigenetic Modulators and the New Immunotherapies","volume":"374","author":"Dear","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0378-1119(02)00397-9","article-title":"Upregulation of prostate specific membrane antigen\/folate hydrolase transcription by an enhancer","volume":"285","author":"Noss","year":"2002","journal-title":"Gene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2021.03.005","article-title":"Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer","volume":"80","author":"Kumaraswamy","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_15","first-page":"220","article-title":"Genetic and epigenetic bases of prostate tumor cell radioresistance","volume":"34","author":"Kutilin","year":"2021","journal-title":"Klin. Onkol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kotzerke, J., Buesser, D., Naumann, A., Runge, R., Huebinger, L., Kliewer, A., Freudenberg, R., and Brogsitter, C. (2022). Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy. Cancers, 14.","DOI":"10.3390\/cancers14102513"},{"key":"ref_17","first-page":"1805","article-title":"Upregulation of Key Molecules for Targeted Imaging and Therapy","volume":"57","author":"Taelman","year":"2016","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7150\/thno.77918","article-title":"Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models","volume":"13","author":"Ullrich","year":"2023","journal-title":"Theranostics"},{"key":"ref_20","first-page":"632","article-title":"Potential for Increasing Uptake of Radiolabeled (68)Ga-DOTATOC and (123)I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat","volume":"36","author":"Pollard","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1002\/ctm2.957","article-title":"Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients","volume":"12","author":"Refardt","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1021\/acs.molpharmaceut.2c00070","article-title":"Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors","volume":"19","author":"Liolios","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000518801","article-title":"Role of Epigenetic Therapy in the Modulation of Tumor Growth and Migration in Human Castration-Resistant Prostate Cancer Cells with Neuroendocrine Differentiation","volume":"112","author":"Dicitore","year":"2022","journal-title":"Neuroendocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MOU.0000000000001027","article-title":"New approaches to targeting epigenetic regulation in prostate cancer","volume":"32","author":"Thompson","year":"2022","journal-title":"Curr. Opin. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sayar, E., Patel, R.A., Coleman, I.M., Roudier, M.P., Zhang, A., Mustafi, P., Low, J.Y., Hanratty, B., Ang, L.S., and Bhatia, V. (2023). Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight, e162907.","DOI":"10.1172\/jci.insight.162907"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"50569","DOI":"10.1021\/acsami.2c15095","article-title":"Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers","volume":"14","author":"Meher","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Luan, X., Zhou, H., Chen, Y., Zhang, X., Cui, M., Chen, K., Xu, X., Zhang, J., and Xu, B. (2022). A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101252"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lfs.2018.02.019","article-title":"Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer","volume":"198","author":"Motawi","year":"2018","journal-title":"Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.5534\/wjmh.220073","article-title":"Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2","volume":"41","author":"Lee","year":"2023","journal-title":"World J. Mens. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/1061186X.2017.1315686","article-title":"Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition","volume":"25","author":"Liu","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_34","first-page":"919","article-title":"PSMA expression on neovasculature of solid tumors","volume":"35","author":"Sathekge","year":"2020","journal-title":"Histol. Histopathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31368","DOI":"10.18632\/oncotarget.15572","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR\u201d","volume":"8","author":"Feldmann","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Capozza, M., Stefania, R., Dinatale, V., Bitonto, V., Conti, L., Grange, C., Skovronova, R., and Terreno, E. (2022). A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112878"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/pros.21315","article-title":"Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats","volume":"71","author":"Feldmann","year":"2011","journal-title":"Prostate"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:36Z","timestamp":1760123376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040538"],"URL":"https:\/\/doi.org\/10.3390\/ph16040538","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}